Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines
The development of vaccines, especially RNA-based, directed against patient-specific tumor neoepitopes is an active and productive area of cancer immunotherapy. Promising clinical results in melanoma and other solid tumor types are emerging. As with all cancer therapy modalities, neoepitope vaccine...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/7/e009595.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850235195166294016 |
|---|---|
| author | Renee N Donahue Jeffrey Schlom James L Gulley James W Hodge Claudia Palena Duane H Hamilton Sofia R Gameiro |
| author_facet | Renee N Donahue Jeffrey Schlom James L Gulley James W Hodge Claudia Palena Duane H Hamilton Sofia R Gameiro |
| author_sort | Renee N Donahue |
| collection | DOAJ |
| description | The development of vaccines, especially RNA-based, directed against patient-specific tumor neoepitopes is an active and productive area of cancer immunotherapy. Promising clinical results in melanoma and other solid tumor types are emerging. As with all cancer therapy modalities, neoepitope vaccine development and delivery also has some drawbacks, including the level of effort to develop a patient-specific product, accuracy of algorithms to predict neoepitopes, and with the exception of melanoma and some other tumor types, biopsies of metastatic lesions of solid tumors are often not available. We hypothesize that in some circumstances the use of rationally designed combinations of “off-the-shelf” agents may prove an additional path to enable the patient to produce his/her own “neoepitope vaccine” in situ. These combination therapies may consist of agents to activate a tumor-associated T-cell response, potentiate that response, reduce or eliminate immunosuppressive entities in the tumor microenvironment, and/or alter the phenotype of tumor cells to render them more susceptible to immune-mediated lysis. Examples are provided in both preclinical and clinical studies in which combinations of “off-the-shelf” agents lead to the generation of T cells directed against tumor-derived neoepitopes with consequent antitumor activity. |
| format | Article |
| id | doaj-art-a0dfb2ad06104e178521dabe0f22daa7 |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-a0dfb2ad06104e178521dabe0f22daa72025-08-20T02:02:20ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-07-0112710.1136/jitc-2024-009595Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccinesRenee N Donahue0Jeffrey Schlom1James L Gulley2James W Hodge3Claudia Palena4Duane H Hamilton5Sofia R Gameiro61Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA2Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA1National Cancer Institute, Bethesda, MD, USACenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USACenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USACenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USACenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USAThe development of vaccines, especially RNA-based, directed against patient-specific tumor neoepitopes is an active and productive area of cancer immunotherapy. Promising clinical results in melanoma and other solid tumor types are emerging. As with all cancer therapy modalities, neoepitope vaccine development and delivery also has some drawbacks, including the level of effort to develop a patient-specific product, accuracy of algorithms to predict neoepitopes, and with the exception of melanoma and some other tumor types, biopsies of metastatic lesions of solid tumors are often not available. We hypothesize that in some circumstances the use of rationally designed combinations of “off-the-shelf” agents may prove an additional path to enable the patient to produce his/her own “neoepitope vaccine” in situ. These combination therapies may consist of agents to activate a tumor-associated T-cell response, potentiate that response, reduce or eliminate immunosuppressive entities in the tumor microenvironment, and/or alter the phenotype of tumor cells to render them more susceptible to immune-mediated lysis. Examples are provided in both preclinical and clinical studies in which combinations of “off-the-shelf” agents lead to the generation of T cells directed against tumor-derived neoepitopes with consequent antitumor activity.https://jitc.bmj.com/content/12/7/e009595.full |
| spellingShingle | Renee N Donahue Jeffrey Schlom James L Gulley James W Hodge Claudia Palena Duane H Hamilton Sofia R Gameiro Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines Journal for ImmunoTherapy of Cancer |
| title | Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines |
| title_full | Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines |
| title_fullStr | Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines |
| title_full_unstemmed | Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines |
| title_short | Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines |
| title_sort | hypothesis the generation of t cells directed against neoepitopes employing immune mediating agents other than neoepitope vaccines |
| url | https://jitc.bmj.com/content/12/7/e009595.full |
| work_keys_str_mv | AT reneendonahue hypothesisthegenerationoftcellsdirectedagainstneoepitopesemployingimmunemediatingagentsotherthanneoepitopevaccines AT jeffreyschlom hypothesisthegenerationoftcellsdirectedagainstneoepitopesemployingimmunemediatingagentsotherthanneoepitopevaccines AT jameslgulley hypothesisthegenerationoftcellsdirectedagainstneoepitopesemployingimmunemediatingagentsotherthanneoepitopevaccines AT jameswhodge hypothesisthegenerationoftcellsdirectedagainstneoepitopesemployingimmunemediatingagentsotherthanneoepitopevaccines AT claudiapalena hypothesisthegenerationoftcellsdirectedagainstneoepitopesemployingimmunemediatingagentsotherthanneoepitopevaccines AT duanehhamilton hypothesisthegenerationoftcellsdirectedagainstneoepitopesemployingimmunemediatingagentsotherthanneoepitopevaccines AT sofiargameiro hypothesisthegenerationoftcellsdirectedagainstneoepitopesemployingimmunemediatingagentsotherthanneoepitopevaccines |